Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67,241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer.
Obradovic A, Graves D, Korrer M, Wang Y, Roy S, Naveed A, Xu Y, Luginbuhl A, Curry J, Gibson M, Idrees K, Hurley P, Jiang P, Liu XS, Uppaluri R, Drake CG, Califano A, Kim YJ. Obradovic A, et al. Among authors: xu y. Clin Cancer Res. 2022 May 13;28(10):2094-2109. doi: 10.1158/1078-0432.CCR-21-3570. Clin Cancer Res. 2022. PMID: 35262677 Free PMC article.
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Johnson DB, et al. Among authors: xu y. Cancer Immunol Res. 2016 Nov;4(11):959-967. doi: 10.1158/2326-6066.CIR-16-0143. Epub 2016 Sep 26. Cancer Immunol Res. 2016. PMID: 27671167 Free PMC article.
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.
Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Stover DG, et al. Among authors: xu q, xu y. NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 29761158 Free PMC article.
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM. Johnson DB, et al. Among authors: xu y. JCI Insight. 2018 Dec 20;3(24):e120360. doi: 10.1172/jci.insight.120360. JCI Insight. 2018. PMID: 30568030 Free PMC article.
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.
Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, de Miranda NFDCC, Trajanoski Z. Finotello F, et al. Among authors: xu y. Genome Med. 2019 May 24;11(1):34. doi: 10.1186/s13073-019-0638-6. Genome Med. 2019. PMID: 31126321 Free PMC article.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Johnson DB, et al. Among authors: xu y. N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214. N Engl J Med. 2016. PMID: 27806233 Free PMC article.
67,241 results
You have reached the last available page of results. Please see the User Guide for more information.